Eliquis Offered to Cash-Paying Patients at More Than 40% Discount to Current List Price, Sotyktu at More Than 80% Discount to Current List Price PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb ...

Beginning January 2026, Sotyktu, BMS’ medicine for moderate-to-severe plaque psoriasis, will be offered through the new BMS Patient Connect platform, which follows the launch of our Bristol Myers ...

Bristol Myers Squibb (NYSE: BMY) today announced an expansion of its direct-to-patient offerings, providing eligible U.S. patients with steeply discounted prices for Eliquis ® (apixaban) and Sotyktu ® ...

Bristol Myers Squibb announced an expansion of its direct-to-patient offerings, providing eligible US patients with steeply discounted prices for Eliquis (apixaban) and Sotyktu (deucravacitinib).